BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.15.17//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250425T090000
DTEND;TZID=Europe/Stockholm:20250425T094000
DTSTAMP:20260313T023547
CREATED:20250408T075501Z
LAST-MODIFIED:20250408T114952Z
UID:184765-1745571600-1745574000@www.scilifelab.se
SUMMARY:Locoregional cancer therapies for uveal melanoma.
DESCRIPTION:Speaker: Roger Olofsson Bagge\, Professor och Överläkare \n\n\n\nAvdelningen för Kirurgi\, Institutionen för kliniska vetenskaper\, Sahlgrenska Akademin\, Göteborgs Universitet\, Sektionen för Bröst och Melanomkirurgi\, Kirurgi\, Sahlgrenska Universitetssjukhuset \n\n\n\nAbstract \n\n\n\nUveal melanoma is a cancer arising from the eye. Prognosis is poor in that patients often develop liver metastases and no effective treatments are currently available. Our recent phase III randomized trial (SCANDIUM) demonstrated the effectiveness of locoregional treatment with isolated hepatic perfusion (IHP) while our translational research suggests that this treatment can activate the immune system. By sensitizing uveal melanoma to immunotherapy\, efficacy of treatment may be further increased as we showed by combining IHP with modern immunotherapy (SCANDIUM-II). \n\n\n\nThe purpose of this randomized clinical trial\, the SCANDIUM-III trial\, is to further explore treatment efficacy with a novel clinical trial combining a locoregional cancer treatment with modern immunotherapy. The specific aim is to evaluate if the combination of minimal-invasive percutaneous hepatic perfusion together with the checkpoint inhibitors ipilimumab and nivolumab can improve response rate and survival. Patients will be included from all regions of Sweden\, and if achieving clinically significant findings from the trial the procedure will likely be incorporated into clinical practice without major delays. \n\n\n\nA major limitation is that we currently lack predictive and prognostic factors. We therefore aim to perform a multimodal precision medicine approach using ctDNA\, proteomics\, metabolomics as well as immuneprofiling in both existing samples (SCANDIUM and SCANDIUM-II) as well as prospectively in the SCANDIUM-III trial\, aiming at correlating multimodal liquid biopsies with tumor response\, progression and survival. \n\n\n\nPatients\, clinical samples\, infrastructure and other resources needed for the project are available through the participating University hospital sites and Comprehensive Cancer Center structures. We use the research infrastructure Clinical Studies Sweden – Gothia Forum for clinical trial support\, Biobank Sweden for biobanking and SciLifeLab for our planned multimodal analysis. \n\n\n\nregistration\n\n\n\nAbout Clinical Talks \n\n\n\nAfter seven successful seasons and over seventy dedicated speakers\, we are excited to continue showcasing the contributions of our diverse clinical\, academic\, and industry Life Science community. This season will feature ten insightful talks following our well-established format. \n\n\n\nThe overarching theme is “How to Achieve Feasible Implementation.” Sessions will be held monthly on Fridays from 09:00 to 09:30 a.m. via Zoom\, with occasional exceptions. Each talk will be followed by an engaging Q&A session\, moderated by standing host Rikard Fred and a guest moderator with subject matter expertise to enrich the discussion. \n\n\n\nIn today’s rapidly evolving post-pandemic landscape\, exploring how academic\, clinical\, and industry research—combined with technological advancements—can drive practical and sustainable solutions is crucial. Join us for an opportunity to gain fresh insights\, expand your knowledge\, and connect with experts shaping the future of Life Sciences!
URL:https://www.scilifelab.se/event/locoregional-cancer-therapies-for-uveal-melanoma/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
END:VCALENDAR